Pharmasset Inc
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | |
|---|---|---|---|
| Revenue | $247,000 | $251,000 | $13.3M |
| Operating income | −$91.6M | −$63.7M | −$52.6M |
| Net income | −$19.9M | −$16.1M | −$55.6M |
| Total assets | $172.2M | $129.8M | — |
| Total liabilities | $17.9M | $25.6M | — |
| Equity | $154.3M | $104.1M | $28.9M |
| EPS (diluted) | — | — | — |
| Shares out. | 75.7M | 68.1M | 53.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −37086.6%
- Net margin
- −8039.3%
- Return on equity
- −12.9%
- Return on assets
- −11.5%
- Return on capital (ROCE)
- −58.8%
- Liabilities / assets
- 10.4%
- Debt / equity
- 0.12×
- Book value / share
- $2.04
- Revenue growth (YoY)
- −1.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Altman Z″ (distress)
- 5.17safe
- Accruals / assets
- 37.3%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Conrad Herbert JDirector | Jan 12, 2012 | U | 17,000 | $137.00 |
| Inouye Michael KDirector | Jan 12, 2012 | U | 22,000 | $137.00 |
| Hahn Elliot FDirector | Jan 12, 2012 | U | 17,000 | $137.00 |
| Carney William JDirector | Jan 12, 2012 | U | 146,330 | $137.00 |
| Williamson Robert F IiiDirector | Jan 12, 2012 | U | 7,000 | $137.00 |
| Leutzinger KurtOfficer — Chief Financial Officer | Jan 12, 2012 | U | 222,232 | $137.00 |
| Price P SchaeferOfficer — President and CEO | Jan 12, 2012 | U | 628,044 | $137.00 |
| Otto Michael J.Officer — Chief Scientific Officer | Jan 12, 2012 | U | 14,378 | $137.00 |
| Berrey M MichelleOfficer — Chief Medical Officer | Dec 1, 2011 | Option exercise | 3,126 | $6.83 |
| Otto Michael J.Officer — Chief Scientific Officer | Nov 1, 2011 | Option exercise | 17,500 | $10.83 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Other material eventJan 17, 2012
- Director / officer changeJan 13, 2012
- Change in control · Director / officer changeJan 12, 2012
- Other material eventDec 22, 2011
- Other material eventDec 16, 2011
- Entered a material agreement · Other material eventNov 21, 2011
- Other material eventNov 4, 2011
- Regulation FD disclosureSep 30, 2011
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 12, 2013
- SC 13G/AFORM SC 13G/AFeb 14, 2012
- SC 13G/AVRUS AS OF 12/31/11Feb 13, 2012
- SC 13GFeb 9, 2012
- SC 13GFeb 2, 2012
- 15-12BFORM 15Jan 19, 2012
- EFFECTJan 18, 2012
- EFFECTJan 18, 2012
- EFFECTJan 18, 2012
- EFFECTJan 18, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Jan 18, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Jan 18, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Jan 18, 2012
- RWREGISTRATION WITHDRAWALJan 18, 2012
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Jan 18, 2012